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Synaptic vesicles loaded with neurotransmitters fuse
with the plasma membrane to release their content
into the extracellular space, thereby allowing neuronal
communication. The membrane fusion process is
mediated by a conserved set of SNARE proteins:
vesicular synaptobrevin and plasma membrane syn-
taxin and SNAP-25. Recent data suggest that the
fusion process may be subject to regulation by local
lipid metabolism. Here, we have performed a screen
of lipid compounds to identify positive regulators of
vesicular synaptobrevin. We show that sphingosine,
a releasable backbone of sphingolipids, activates
synaptobrevin in synaptic vesicles to form the SNARE
complex implicated in membrane fusion. Consistent
with the role of synaptobrevin in vesicle fusion, sphin-
gosine upregulated exocytosis in isolated nerve
terminals, neuromuscular junctions, neuroendocrine
cells and hippocampal neurons, but not in neurons
obtained from synaptobrevin-2 knockout mice.
Further mechanistic insights suggest that sphingo-
sine acts on the synaptobrevin/phospholipid inter-
face, defining a novel function for this important lipid
regulator.
INTRODUCTION
Neurotransmission occurs when synaptic vesicles loaded with
neurotransmitters fuse with the plasma membrane causing
release of their content. This neuronal exocytosis requires three
SNARE (soluble-N-ethylmaleimide sensitive factor attachment
protein receptor) proteins: synaptobrevin-2 (also known as
VAMP-2) on the synaptic vesicle, and syntaxin-1 with SNAP-25on the plasma membrane (Jahn and Scheller, 2006; Sollner,
2003; Sudhof and Rothman, 2009). Formation of the SNARE
ternary complex by the three proteins is an essential step toward
membrane fusion.
It is critical for neuronal physiology that synaptic vesicle
exocytosis takes place with high spatial and temporal precision.
Preventing uncontrolled formation of SNARE complex can be an
important point for regulation of vesicle fusion and thereby of
neurotransmission. Interestingly, synaptobrevin in synaptic vesi-
cles does not readily react with syntaxin and SNAP-25 (Hu et al.,
2002). Two alternative mechanisms could account for constitu-
tive downregulation of synaptobrevin activity: synaptophysin,
a small synaptic vesicle marker, can interact with synaptobre-
vin’s transmembrane part (Edelmann et al., 1995; Yelamanchili
et al., 2005) and the cytoplasmic part of synaptobrevin has
been shown to interact with lipid membranes (Caccin et al.,
2003; Quetglas et al., 2000). Recent studies highlighted a likely
role of lipid metabolism in regulation of vesicle fusion (Bankaitis
and Morris, 2003; Fivaz and Meyer, 2003; Humeau et al., 2001;
Rohrbough and Broadie, 2005; Sollner, 2007; Wenk and De
Camilli, 2004). Since vesicular properties of synaptobrevin
must be essential in SNARE-mediated membrane fusion, we
decided to screen a library of lipid compounds using isolated
synaptic vesicles to gain insight into possible regulators of syn-
aptobrevin function. We now show that sphingosine, an essential
releasable constituent of cell membranes (Hannun and Obeid,
2008; Lahiri and Futerman, 2007; Posse de Chaves, 2006), can
potently activate synaptobrevin and also enhance SNARE-medi-
ated synaptic vesicle exocytosis.
RESULTS
Identification of Sphingosine as an Activator
of Vesicular Synaptobrevin
For screening of lipids with a potential role in exocytosis, we
purified synaptic vesicles from rat brain by a flotation procedureNeuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc. 683
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Activation of Synaptobrevin by Sphingosine(Hu et al., 2002) and incubated them with preassembled soluble
syntaxin1/SNAP-25 heterodimers in the presence of various lipid
compounds (Table 1) for 30 min at 22C. A hallmark of the
neuronal SNARE complex is its resistance to dissociation by
chaotropic agents and detergents, even SDS (Hu et al., 2002).
Therefore synaptobrevin’s ability to engage syntaxin/SNAP-25
can be analyzed through the formation of SDS-resistant SNARE
complexes. This analysis was done by Western immunoblotting
using a monoclonal antibody which detects both the free and
engaged forms of synaptobrevin. Lipids were regarded as syn-
aptobrevin activators if, at 50 mM concentration, they could
promote formation of the SNARE complexes, at the same time
decreasing the amount of monomeric synaptobrevin (Figure 1A).
Remarkably, among the molecules tested, only sphingosine and
some of its derivatives were able to stimulate synaptobrevin in
synaptic vesicles (Table 1 and Figure 1A). We tested synaptobre-
vin availability using the soluble part of syntaxin (aa 1–261)
preassembled with either brain SNAP-25 (Hu et al., 2002),
wild-type recombinant SNAP-25 or recombinant SNAP-25 in
which four cysteines were mutated (Siddiqui et al., 2007). Sphin-
gosine activated synaptobrevin regardless of which SNAP-25
was used (Figure 1A). No synaptobrevin-containing assemblies
were observed if syntaxin and/or SNAP-25 were omitted (data
not shown). Since sphingosine (Figure 1B) is an essential constit-
uent of neuronal membranes, which can be enzymatically
released into the cytosol, and its levels significantly change in
brain pathologies and with aging (Colombaioni and Garcia-Gil,
2004; Dasgupta et al., 2007; He et al., 2008), we decided to
investigate the sphingosine effect in detail.
Titration experiments demonstrated that sphingosine allows
synaptobrevin to form ternary SNARE complexes in a dose-
dependent manner, with an EC50 10 mM (Figure 1C). Although
micromolar sphingosine concentrations are used in cellular
experiments, it was important to rule out a possibility of sphingo-
sine compromising the integrity of synaptic vesicle membranes.
We therefore employed two approaches. First, synaptic vesicles
were incubated with or without 50 mM sphingosine and the reac-
tions were analyzed by negative-stain electron microscopy.
Figure 1D shows that synaptic vesicle membranes appear intact
after one hour incubation in the presence of 50 mM sphingosine.
Second, we employed a flotation assay where synaptic vesicles,
with or without sphingosine, were floated on a discontinuous Op-
tiprep gradient. The presence of synaptobrevin in the samples
was probed by immunoblotting. Figure 1E shows that synapto-
brevin remains firmly associated with synaptic vesicles (top frac-
tion) following the sphingosine treatment.
Sphingosine Activates Vesicle Exocytosis
To test whether sphingosine can activate exocytosis we used
a whole-cell patch-clamp setup. Sphingosine was dialyzed into
the cytosol of cultured rat pituitary intermediate lobe cells (mela-
notrophs), which express synaptobrevin-2 (Jacobsson and
Meister, 1996). We then measured membrane capacitance
(Cm), a parameter linearly related to the plasma membrane
area, which increases upon exocytosis (Neher and Marty,
1982). The cytosol dialysis with 1 mM Ca2+ resulted in an increase
in Cm of 16.7% ± 6.5%. Inclusion of 10 mM sphingosine into the
patch pipette solution doubled the average Ca2+-dependent684 Neuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc.increase in Cm (36.5% ± 7.2%; Figures 2A and 2B). With 50 mM
sphingosine in the pipette solution, the increase in Cm was
49% ± 8.6% (Figures 2A and 2B). In the absence of stimulating
calcium in the pipette, cytosol dialysis of sphingosine (50 mM)
did not significantly affect Cm (Figures 2C and 2D). The patch-
clamp capacitance experiments were also performed with
bovine chromaffin cells but in this case exocytosis was triggered
by electrical stimulation. Two minutes after establishing the whole
cell configuration, 200 ms depolarizing pulses were applied at
1 min intervals. Dialyzed sphingosine at 10 mM and 50 mM con-
centrations enhanced the secretory response in chromaffin cells
1.2- and 1.6-fold, respectively (see Figure S1 available online).
In the absence of stimulation, addition of sphingosine did not
significantly change resting membrane capacitance (control:
8.5 ± 0.5 pF; 10mM sphingosine: 7.7 ± 0.4 pF; 50 mM sphingosine:
7.8 ± 0.4 pF). Together, these results indicate that sphingosine-
mediated increase in the plasma membrane area is likely due to
enhanced vesicle exocytosis rather than simple incorporation
of the lipid into the membrane.
To test sphingosine action on synaptic vesicle exocytosis, we
first investigated the ability of externally added sphingosine, an
amphiphilic lipid, to penetrate biological membranes. We incu-
bated rat brain nerve terminals (synaptosomes) with radioactive
sphingosine for 10 min and after a wash step disrupted synapto-
somes by hypo-osmotic shock. Following separation of synaptic
fractions by centrifugation, distribution of sphingosine in synaptic
membranes, synaptic cytosol and synaptic vesicles was
analyzed by liquid scintillation (Figure 3A). Sphingosine distrib-
uted equally between synaptic membranes and vesicles with
a small amount being present in cytosol when normalized to the
amount of protein. We then probed potassium-stimulated gluta-
mate release from nerve terminals isolated from adult rat brain
using a fluorometric assay (McMahon et al., 1992). Pretreatment
of synaptosomes with sphingosine for 10 min before addition of
potassiumsignificantlyaugmentedglutamate release (Figure3B).
To probe whether the sphingosine effect is indeed linked to
exocytosis of small synaptic vesicles, we analyzed miniature
endplate potentials (MEPPs) in mouse neuromuscular junctions.
Sphingosine increased frequency of MEPPs by 30% without
changes in their amplitude (Figure 3C). Next, we tested sphingo-
sine action in sucrose-evoked exocytosis reflecting the readily
releasable pool of synaptic vesicles (Figure 3D). In control exper-
iments, two transient (1 min long) local applications of 60 mM
sucrose to synaptic regions with an interval of 60 min produced
equal bursts of quantal events (Figure 3D; test-2/test-1 ratio is
104.1% ± 8.6%). In the presence of 50 mM sphingosine, however,
the second peak response was significantly augmented
(Figure 3D; test-2/test-1 ratio is 140.7% ± 10.1%) indicating
a larger pool of readily releasable vesicles.
SNARE-Mediated Mechanisms Account
for the Sphingosine Action in Exocytosis
To test whether sphingosine action involves synaptobrevin, we
probed its effects in a synaptobrevin knockout model (Syb2/).
Mice deficient in synaptobrevin-2 die immediately after birth;
however, embryonic neurons from these animals survive in
culture (Deak et al., 2004; Schoch et al., 2001). Heterozygous
mice, on the other hand, are viable and have normal synaptic
Neuron
Activation of Synaptobrevin by SphingosineTable 1. Lipids Tested as Potential Activators of Vesicular Synaptobrevin
Lipid Name Activation Lipid Name Activation Lipid Name Activation
(±)4-Hydroxynon-2-enal  AGC  12-Methoxydodecanoic acid 
Epoxy-oleic acid  Farnesylthioacetic acid  Sphingomyelin 
Prostaglandin A1  25-Hydroxyvitamin D3  D-erythro-Sphingosine +
Prostaglandin A2  1,25-Dihydroxyvitamin D3  L-erythro-sphingosine +
Prostaglandin B1  24,25-Dihydroxyvitamin D3  D-erythro-N,N-Dimethylsphingosine +
Prostaglandin B2  Retinoic acid, all trans  D-erythro-N,N,
N-trimethylsphingosine
+
Prostaglandin E1  9-cis Retinoic acid  D-erythro-Dihydrosphingosine +
Prostaglandin F1a  13-cis Retinoic acid  DL-threo-Dihydrosphingosine +
Prostaglandin I2 Na  4-Hydroxyphenylretinamide  D-erythro-Sphingosylphosphoryl
choline
+
15-Keto-prostaglandin E2  AM-580  D-erythro-Sphingosine-1-
phosphate

15-Keto-prostaglandin F2a  TTNPB  Dihydro-sphingosine-1-phosphate 
13,14-Dihydro-15-keto-prostaglandin
F2a
 Methoprene acid  D-erythro-N-Acetylsphingosine 
6-Keto-prostaglandin F1a  WY-14643  D-erythro-N-Acetylsphinganine 
16,16-Dimethyl-prostaglandin E2  Ciglitazone  D-erythro-N-Octanoylsphingosine 
U-46619  Clofibrate  D-erythro-N-Octanoylsphinganine 
9b,11a Prostaglandin F2  5,8,11-Eicosatriynoic acid  D-erythro-N-Palmitoylsphingosine 
9a,11b Prostaglandin F2  5,8,11,14-Eicosatetraynoic acid  DL-PDMP
Prostaglandin J2  1,2-Didecanoyl-glycerol (10:0)  DL-PPMP 
Carbacyclin  1,2-Dioctanoyl-SN-glycerol  MAPP, D-erythro 
(±)13-Azaprostanoic acid  1,2-Dioleoyl-glycerol (18:1)  MAPP, L-erythro 
19(R)-Hydroxy-prostaglandin E2  1-Oleoyl-2-acetyl-glycerol  PAF C16 
17-Phenyl-trinor-prostaglandin E2  1-Stearoyl-2-arachidonoyl-glycerol  Lyso-PAF C16 
D12-Prostaglandin J2  Ricinoleic acid  PAF C18 
13,14-Dihydro-prostaglandin E1  1-Hexadecyl-2-arachidonoyl-
glycerol
 PAF C18:1 
8-epi-Prostaglandin F2a  1-Hexadecyl-2-O-methyl-glycerol  Enantio-PAF C16 
15-Deoxy-D12,14-prostaglandin J2  1-Hexadecyl-2-O-acetyl-glycerol  Arachidonoyl-PAF 
Misoprostol, free acid  REV-5901  2-EPA-PAF 
Thromboxane B2  LY-171883  2-DHLA-PAF 
11-Dehydro-thromboxane B2  SQ-29548  2-DCHA-PAF 
Anandamide (20:4, n-6)  Fluprostenol  1-Hexadecyl-2-methylglycero-3 PC 
Palmitylethanolamide  Cloprostenol Na  1-Octadecyl-2-methylglycero-3 PC 
Anandamide (18:2,n-6)  Eicosapentaenoic acid (20:5, n-3)  C-PAF 
Anandamide (20:3,n-6)  Gamma-linolenic acid (18:3, n-6)  1-Acyl-PAF 
Anandamide (22:4,n-6)  Eicosatrienoic acid (20:3, n-3)  Lysophosphatidic acid 
Mead ethanolamide  Dihomo-gamma-linolenic acid  L-NASPA 
(R)-Methanandamide  Docosatrienoic acid  Phosphatidic acid, dipalmitoyl 
BML-190  Adrenic acid (22:4, n-6)  AM-251 
N-Arachidonoylglycine  Docosapentaenoic acid  6-Formylindolo [3,2-b] carbazole 
WIN 55,212-2  Arachidonic acid  Diindolylmethane 
Arachidonamide  Docosahexaenoic acid  N-Linoleoylglycine 
Linoleamide  17-Octadecynoic acid  Palmitoyl dopamine 
9,10-Octadecenoamide  2-Hydroxymyristic acid  Oleoyl dopamine 
Acetyl-farnesyl-cysteine  2-Fluoropalmitic acid  Arachidonoyl dopamine 
AGGC  4-Oxatetradecanoic acid 
+ indicates positive regulators.  indicates inactive compounds. Sphingolipids are in bold.Neuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc. 685
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Figure 1. Sphingosine Activates Synapto-
brevin in Synaptic Vesicles for SNARE
Assembly
(A) Rat brain synaptic vesicles were mixed with
syntaxin/SNAP-25 made with syntaxin 1A (aa
1–261) and either brain-purified, recombinant
wild-type (WT), or recombinant SNAP-25 devoid
of cysteines (SNAP-25 C/A) in the presence of
indicated lipids. Following 30 min incubation at
22C the reactions were analyzed by SDS-PAGE
and western immunoblotting using an anti-synap-
tobrevin antibody. Note mass transition of mono-
meric synaptobrevin into the SNARE complex in
the case of sphingosine and its derivative tri-
methyl-sphingosine.
(B) Chemical structure of sphingosine, a backbone
lipid of cellular membranes.
(C) Titration of sphingosine indicates EC50 of 10 mM.
Inset, representative immunoblot of synaptic vesi-
cles showing sphingosine-dependent transition of
monomeric synaptobrevin into the SNARE
complex. Error bars represent SEM, n = 7.
(D) Negative stain electron microscopy images
demonstrating that 50 mM sphingosine does not
affect overall morphology of synaptic vesicles.
(E) Left panel shows a schematic outline of the
flotation experiment. Immunoblot (right panel)
shows that synaptobrevin cofloats with synaptic
vesicles to the top of the discontinuous Optiprep
gradient following treatment with 50 mM sphingo-
sine. Syb, synaptobrevin.characteristics. In cultures obtained from heterozygous mice,
application of 50 mM sphingosine caused a 2.7-fold increase in
the amplitudes of excitatory postsynaptic currents (EPSCs)
induced by field stimulation (Figure 4A). Syb2/ neurons exhibit
a severe reduction in evoked exocytosis and endocytosis espe-
cially in response to stimulation at low frequencies (1 Hz). Never-
theless, in some cells one can detect occasional responses to
stimulation and sphingosine effects were tested in these re-
sponding cells. The responses recorded from Syb2/ synapses686 Neuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc.did not show an increase after sphingosine treatment (Figure 4A).
In contrast to field-evoked stimulation, Syb2/ neurons repro-
ducibly respond to hypertonic sucrose stimulation albeit at
a reduced level (6% compared to nontreated wild-type
neurons; Schoch et al., 2001). Heterozygous neurons treated
with sphingosine had a 2-fold increase in their responses to
hypertonic sucrose application compared to neurons from
nontreated heterozygous cultures. Sphingosine-treated Syb2/
neurons, however, did not exhibit a significant increase in theirFigure 2. Sphingosine Dialyzed into Rat Pituitary Mel-
anotrophs Enhances Exocytosis
(A) Graphs showing calcium-induced changes in membrane
capacitance (Cm) measured by the patch-clamp technique.
Sphingosine augments the increase in Cm. Dashed lines
denote resting Cm values.
(B) The difference in Cm (DCm) was measured 300 s following
the establishment of the whole-cell recording as indicated in
(A). Mean DCm expressed as percentage relative to the resting
Cm. Dialyzed sphingosine increased amplitudes 2-fold at
10 mM (n = 15 cells; *p% 0.05) and 3-fold at 50 mM (n = 15 cells;
**p < 0.01) relative to the control (n = 16 cells).
(C) Graphs showing changes in Cm in the absence of stimu-
lating calcium. Dialysis of sphingosine at 50 mM into the
cytosol led to a small increase in Cm.
(D) Bar chart showing that sphingosine does not significantly
affectDCm measured as indicated in (C) (control: n = 10; 50 mM
sphingosine: n = 15; p > 0.1). The Student’s t test was used for
pairwise comparisons. In the bar charts, error bars represent
SEM.
Neuron
Activation of Synaptobrevin by SphingosineC
D
B
A
Figure 3. Sphingosine Incorporates into Synaptic Vesicles and Stim-
ulates Vesicle Exocytosis in Synaptosomes and Neuromuscular
Junctions
(A) Radioactive sphingosine (50 mM) added to rat brain synaptosomes can
reach synaptic vesicles. Left panel, schematic describing the procedure for
isolation of synaptic fractions. Right panel, bar chart showing that externally
added sphingosine incorporates into both synaptic membranes and synaptic
vesicles whereas only small amounts of sphingosine are present in the cytosol.
(B) Left panel, sphingosine treatment (20 mM) enhances potassium-evoked,
calcium-dependent glutamate release from isolated synaptosomes. Curves
are from an experiment performed in triplicates (paired t test, p < 0.001). Right
panel, end-point calcium-dependent release measured after 10 min of stimu-
lation. Sphingosine enhances glutamate release by 27% (Student’s t test,
n = 9; **p < 0.001).
(C) Left panel, cumulative distribution of inter-event intervals of miniature end-
plate potentials (MEPPs) in a mouse neuromuscular synapse before and after
application of 50 mM sphingosine. Right panel, cumulative distribution of MEPP
amplitudes before and after application of 50 mM sphingosine. Note that sphin-
gosine increases frequency but does not change the amplitude of MEPPs.
(D) Sucrose-evoked quantal release at the neuromuscular junction before and
after application of 50 mM sphingosine. Right panel, averaged data of two
consecutive sucrose applications (test-1 followed by test-2 in 60 min). Test-
2 was performed either in the absence (control, n = 4; p > 0.05) or presence
of sphingosine (n = 5; Mann-Whitney test, *p < 0.05). Data are presented as
test-2 to test-1 ratio. In the bar charts, error bars represent SEM.hypertonic sucrose responses compared with nontreated
neurons (Figure 4B). Together these results indicate that synap-
tobrevin is necessary for the sphingosine-induced increase in
vesicle fusion.
To probe the ability of sphingosine to promote SNARE as-
sembly inside neurons, we utilized the fact that botulinum neuro-
toxins can proteolyze monomeric but not assembled SNAREs
(Hayashi et al., 1994). We employed botulinum neurotoxins D
and E which can enter neurons and specifically cleave synapto-
brevin and SNAP-25, respectively. Hippocampal neurons were
incubated in the presence or absence of both sphingosine and
neurotoxins for 30 min and then total amounts of monomeric
synaptobrevin and SNAP-25 were analyzed by western immuno-
blotting. Figure S2 shows that application of sphingosine to
neurons impeded proteolysis of synaptobrevin and SNAP-25
by the neurotoxins demonstrating upregulation of SNARE
assembly.
Activation of Exocytosis by Endogenous Production
of Sphingosine
The signaling action of diffusible lipids depends on their release
from the membrane environment through enzyme actions.
Endogenous sphingosine can be released from membranes
through the sequential action of sphingomyelinases and ce-
ramidases (Figure 5A): sphingomyelinase produces apolar ce-
ramide which can flip-flop within lipid bilayer (Contreras
et al., 2005) and be hydrolyzed by intracellular ceramidases re-
sulting in the release of amphiphilic sphingosine into the
cytosol (Hannun and Obeid, 2008; Lahiri and Futerman, 2007;
Van Meer et al., 2008). We first probed the effect of sphingo-
myelinase action on calcium-dependent glutamate release
from isolated rat brain nerve endings. Preincubation of synap-
tosomes with sphingomyelinase for 10 min followed by addition
of 35 mM potassium led to a robust enhancement of Ca2+-
dependent glutamate release (Figure 5B). Importantly, botu-
linum neurotoxin D, which proteolyses vesicular synaptobrevin,
abolished sphingomyelinase-enhanced glutamate release
supporting the conclusion that synaptobrevin is necessary
for the sphingosine-mediated enhancement of exocytosis
(Figure 5B).
A recent study demonstrated that a mutation of a ceramidase
in the Drosophila model organism leads to a significant decrease
of neurotransmission (Rohrbough et al., 2004) prompting us to
employ a ceramidase inhibitor, N-oleoylethanolamine (NOE)
(Strelow et al., 2000). Rat brain synaptosomes were preincu-
bated with 150 mM NOE before addition of sphingomyelinase
and potassium-triggered depolarization. Figure 5B shows that
the ceramidase inhibitor was able to prevent sphingomyeli-
nase-driven enhancement of calcium-dependent glutamate
release from the bulk population of central nerve terminals.
Next, we assessed action of sphingomyelinase on sucrose-
evoked exocytosis which reflects the readily releasable pool of
synaptic vesicles (Rosenmund and Stevens, 1996). Addition of
sphingomyelinase to cultured mouse hippocampal neurons led
to a significant enhancement of hypertonic sucrose-induced
transmitter release whereas pre-incubation with the ceramidase
inhibitor, NOE, blocked the sphingomyelinase effect (Figure 5C).
Together, these data show that enzymatically-producedNeuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc. 687
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effect on synaptic vesicle exocytosis.
Effects of Sphingosine Derivatives on Activation
of Synaptobrevin and Exocytosis
Since sphingosinecanbe metabolized inneurons intosphingosine-
1-phosphate or back into ceramide, it was necessary to analyze
sphingosine analogs which cannot be modified in vivo. For testing,
we chose two chemical derivatives—dihydrosphingosine and
N-acetylsphinganine, the former being positive regulator of synap-
tobrevinandthe latterbeing ineffective inour synaptic vesicle assay
(Table 1 and Figures 6A and 6B). Addition of dihydrosphingosine to
neurons resulted in an increase in both average maximum ampli-
tudes of field potential-stimulated EPSCs (Figure 6B; 2.2-fold)
and the hypertonic sucrose responses (Figure 6C; 1.7-fold)
compared to neurons treated with vehicle only. In contrast, incuba-
tion of neurons with 50 mM N-acetylsphinganine resulted in no
significant differences in either EPSC amplitudes or hypertonic
sucrose responses (Figure S3). Thus, neurotransmitter release
remains unchanged in the presence of N-acetylsphinganine, an
ineffective synaptobrevin modulator. In contrast, dihydrosphingo-
sine can both enhance synaptobrevin activity in SNARE reactions
and cause potentiation of excitatory neurotransmitter release.
Mechanism of Sphingosine Action on Vesicular
Synaptobrevin
Since synaptobrevin resides in synaptic vesicle membrane
among a dense network of proteins (Takamori et al., 2006), we
probed whether sphingosine acts on the synaptobrevin/
A
B
Figure 4. Synaptobrevin-2 Involvement in Sphingo-
sine-Enhanced Transmitter Release
(A) Left panel, representative traces of excitatory postsynaptic
currents (EPSCs) evoked by field stimulation in Syb2+/ or syn-
aptobrevin-2-deficient (Syb2/) neurons treated with 50 mM
sphingosine or vehicle (control). Arrows indicate application
of the current. Right panel, bar chart showing a significant
increase in the average maximum EPSC amplitudes of sphin-
gosine-treated wild-type neurons compared to nontreated
control neurons (control, n = 5; sphingosine, n = 5; *p < 0.03).
No difference in amplitudes was detected in sphingosine-
treated compared to nontreated Syb2/ neurons (control,
n = 5; sphingosine, n = 5, p > 0.72).
(B) Left panel, representative traces of hypertonic sucrose-
induced (gray bars) transmitter release in Syb2+/ and Syb2/
neurons treated with either 50 mM sphingosine or vehicle. Right
panel, bar chart of the charge transfer during the first 10 s of
sucrose stimulation showing a 2-fold increase in wild-type
(control, n = 11; sphingosine, n = 17; **p < 0.002) and no
increase in Syb2/ neurons (control, n = 14; sphingosine,
n = 17; p > 0.22) after sphingosine addition. In the bar charts,
error bars represent SEM. Syb2, synaptobrevin-2. The
Student’s t test was used for pairwise comparisons.
membrane interface, or targets synaptobrevin inter-
action with other vesicular proteins. We reconsti-
tuted full-length recombinant synaptobrevin into
phospholipid liposomes containing phosphatidyl-
choline and phosphatidylserine (3:1 molar ratio).
Figure 7A shows Coomassie-stained protein
content of pure synaptic vesicles and reconstituted proteolipo-
somes; in the latter case, synaptobrevin is distributed equally in
the outer and inner leaflets of liposomal membrane as assessed
by trypsinolysis (Hu et al., 2002). Similar to vesicular synaptobre-
vin, liposomal synaptobrevin was inactive for interaction with
syntaxin and SNAP-25 (Figure 7B), demonstrating that phospho-
lipid membrane is sufficient for synaptobrevin restriction. Reveal-
ingly, sphingosine was sufficient to overcome synaptobrevin
restriction in liposomes when added in a similar concentration
range to that required for activation of synaptobrevin in synaptic
vesicles (Figures 7B and 1C). In contrast, when we incorporated
syntaxin/SNAP-25 into liposomes and tested SNARE assembly
in the presence of a soluble part of synaptobrevin, sphingosine
did not enhance the ability of this membrane-free synaptobrevin
to form SNARE complex with syntaxin and SNAP-25 (Figure S4).
Thus, membrane-embedded syntaxin/SNAP-25 heterodimers
are available for SNARE assembly and sphingosine appears to
affect specifically synaptobrevin in lipid membranes.
Several studies demonstrated the ability of the cytosolic part of
synaptobrevin (amino acids 1–96) to directly interact with nega-
tively charged phospholipid membranes (Caccin et al., 2003; de
Haro et al., 2004; Quetglas et al., 2000). We analyzed whether
sphingosine could compromise the ability of the cytoplasmic
domain of synaptobrevin (aa 1–96) to bind fluorescently-labeled
phospholipid liposomes in a standard pull-down procedure (Dav-
letov and Sudhof, 1993). Binding of liposomes to synaptobrevin
1–96 immobilized on beads was significant as assessed by
bound fluorescence (Figure 7C). When the reactions were
repeated in the presence of sphingosine, the liposomal binding688 Neuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc.
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A Figure 5. Sphingomyelinase-Enhanced Release of
Neurotransmitters Is Blocked by Synaptobrevin-
Cleaving BotulinumNeurotoxin D and by aCeramidase
Inhibitor
(A) Schematic of enzymatic release of endogenous sphingo-
sine from membrane sphingomyelin. Sphingomyelinase
(SMase) initiates hydrolysis of sphingomyelin, while sphingo-
sine is released by ceramidase which can be blocked by
N-oleoylethanolamine (NOE).
(B) Left panel, SMase treatment (1 unit/ml) enhances KCl-
evoked, calcium-dependent glutamate release from synapto-
somes. Botulinum toxin D (BoNT/D, 6 nM) potently blocks
SMase-enhanced glutamate release. Right panel, bar graph
showing normalized glutamate release following 10 min stimu-
lation by KCl. SMase (1 unit/ml) and ceramidase inhibitor, NOE
(150 mM) were added 15 and 30 min before addition of KCl,
respectively (n = 5 *p < 0.05).
(C) Left panel, representative traces of hypertonic sucrose-
induced (gray bars) neurotransmitter release in rat hippo-
campal cultured neurons treated for 10 min with SMase
(1 unit/ml) or an equal volume of vehicle (control), as well as
responses from cells that were pretreated for 15 min with
NOE (150 mM). Right panel, bar chart of the charge transfer
during the first 10 s of sucrose stimulation showing a 2.5-fold
increase in SMase-treated neurons (control, n = 7; SMase,
n = 10; *p < 0.05) and no increase in NOE pretreated neurons
(NOE, n = 11; NOE and SMase, n = 7). In the bar charts, error
bars represent SEM. The Student’s t test was used for pairwise
comparisons.to immobilized synaptobrevin 1–96 was severely compromised
with an EC50 of 6 mM (Figure 7C). To probe whether sphingosine
can affect a preexisting synaptobrevin/membrane interaction, we
followed membrane binding by GST-synaptobrevin (aa 1–96) in
real time using a spectrophotometric assay. This assay detects
crosslinking of liposomes by lipid-binding proteins which are di-
merized by the GST tag (Connell et al., 2008). GST-synaptobrevin
1–96 was first injected into liposomal solution followed by addi-
tion of a sphingosine-containing solution and the two-step reac-
tion was continuously recorded. Addition of the synaptobrevin
construct led to an immediate increase in membrane crosslinking
(Figure 7D). Sphingosine at 50 mM concentration efficiently
reversed liposomal cross-linking (Figure 7D) demonstrating that
it can act even after the onset of synaptobrevin/phospholipid
interaction. We also tested the well-documented binding of the
synaptotagmin C2A domain to the liposomes (Connell et al.,
2008; Davletov and Sudhof, 1993). This interaction occurs strictly
in a calcium-dependent manner and plays a role in calcium-
dependent triggering synaptic vesicle exocytosis (Fernandez-
Chacon et al., 2001). Figure 7E shows that sphingosine was
ineffective in disrupting synaptotagmin/membrane binding,
highlighting a specific mode of action of sphingosine on vesicular
synaptobrevin and also indicating that sphingosine does not
compromise integrity of phospholipid liposomes. Together, our
biochemical results suggest that sphingosine activates vesicular
synaptobrevin for SNARE assembly by liberating its cytosolic part
from a restriction by the resident phospholipid membranes.
To confirm the ability of sphingosine to affect synaptobrevin
properties on the membranes, we performed a limited proteolysis
experiment. We noticed that the V8 protease at 0.1 mM concen-tration cannot readily digest synaptobrevin in synaptic vesicles.
Addition of sphingosine allowed almost complete proteolysis of
synaptobrevin but not of a control protein, synaptophysin (Fig-
ure 7F). In contrast, neither sphingomyelin, ceramide nor sphin-
gosine-1-phosphate were able to promote synaptobrevin diges-
tion. This result confirms that, in the sphingomyelin pathway,
sphingosine is the key metabolite that affects biochemical prop-
erties of vesicular synaptobrevin. Unlike other sphingomyelin
metabolites, sphingosine carries a positive charge at physiolog-
ical pH due to its free amino group (pKa 8.5; Bottega et al., 1989).
To better understand the mechanism of action of sphingosine on
vesicular synaptobrevin, we analyzed the requirement of specific
groups using ten related compounds (natural and synthetic). Two
unique characteristics of sphingosine were identified to be
important for synaptobrevin activation—the positive charge
and the length of the carbon tail. Indeed, both acetylation of the
amino group and phosphorylation of the terminal hydroxyl are
sufficient to neutralize the positive charge making ceramides
and sphingosine-1-phosphate inactive toward vesicular synap-
tobrevin (Figure S5). Short C12-sphingosine was also inactive
demonstrating importance of the long carbon tail of sphingosine.
The fact that L-sphingosine was as effective as the natural D-ster-
eoisoform (Figure S5) demonstrates that the activation of synap-
tobrevin is not due to a ‘‘lock-and-key’’ mechanism but rather
involves a perturbation of the local synaptobrevin environment.
DISCUSSION
A number of recent studies highlighted the physiological sig-
nificance of sphingolipid metabolism in vesicle exocytosis.Neuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc. 689
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release from cerebellar and mesencephalic neurons and also
PC12 cells (Blochl and Sirrenberg, 1996; Jeon et al., 2005;
Numakawa et al., 2003). A recent genetic study has provided
evidence for direct involvement of a ceramidase in synaptic
transmission (Rohrbough et al., 2004). Furthermore, a down-
stream sphingosine metabolite was shown to upregulate gluta-
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Figure 6. Specific Actions of Dihydrosphingosine, a Sphingosine
Mimetic, in SNARE Assembly and in Neurotransmitter Release
Experiments
(A) Rat brain synaptic vesicles (1 mg protein) were mixed with soluble syntaxin/
SNAP-25 in the presence of indicated lipids (50 mM) and analyzed as in
Figure 1. SNARE assembly takes place in the presence of sphingosine and di-
hydrosphingosine, but not in the presence of N-acetylsphinganine.
(B) Dihydrosphingosine addition potentiates excitatory neurotransmitter
release evoked by field potentials in hippocampal neurons. Left panel, repre-
sentative traces of EPSCs evoked by field stimulation in wild-type rat hippo-
campal neurons following treatment with 50 mM dihydrosphingosine or control
(DMSO). Arrows indicate the application of current. Right panel, a plot of the
average maximum EPSC amplitudes depicting a significant increase in the
amplitudes from neurons treated with dihydrosphingosine compared to non-
treated neurons (Control, n = 5, Dihydrosphingosine, n = 5; *p < 0.03).
(C) Dihydrosphingosine addition potentiates excitatory neurotransmitter
release evoked by hypertonic sucrose (gray bars) in hippocampal neurons.
Left panel, representative traces of hypertonic sucrose responses from
neurons incubated with either DMSO or dihydrosphingosine. Right panel,
bar chart of the charge transfer during the first 10 s of sucrose stimulation
showing an increase in dihydrosphingosine-treated neurons compared to
control neurons (Control, n = 5, Dihydrosphingosine, n = 5; *p < 0.03). In the
bar charts, error bars represent SEM. The Student’s t test was used for pair-
wise comparisons.690 Neuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc.mate secretion in primary hippocampal neurons (Kajimoto
et al., 2007) and spontaneous acetylcholine release at the frog
neuromuscular junction (Brailoiu et al., 2002). While ceramide
and sphingosine-1-phosphate have been investigated exten-
sively, there is little information about potential ability of sphingo-
sine to regulate vesicle exocytosis (Colombaioni and Garcia-Gil,
2004). Through the screen of lipid compounds, we determined
that sphingosine can potently and with high specificity activate
vesicular synaptobrevin to form the ternary SNARE complex,
an essential step in vesicle fusion. We also showed that sphingo-
sine can enhance vesicle exocytosis in neuromuscular junctions,
hippocampal neurons, brain synaptosomes and neuroendocrine
cells. Both synaptobrevin-knockout and botulinum neurotoxin
experiments (Figures 4 and 5B) indicated that synaptobrevin is
necessary for the sphingosine-mediated enhancement of exocy-
tosis.
Our results suggest that sphingosine can relief membrane-
mediated inhibition of the cytoplasmic part of synaptobrevin,
thereby allowing formation of the ternary SNARE complex. It is
conceivable that the positively charged sphingosine can locally
disrupt electrostatic and hydrophobic interactions of the cyto-
plasmic part of synaptobrevin with vesicular membranes. Of
note, the cytoplasmic part of synaptobrevin carries basic amino
acids centered around hydrophobic tryptophans, all of which
can contribute to its interaction with negatively charged phos-
pholipid membranes (Kweon et al., 2003; Quetglas et al.,
2000). Recently a consensus has emerged that even in simplified
liposomal systems SNARE-mediated fusion requires certain
activating mechanisms (Mahal et al., 2002; Tucker et al., 2004;
but see Siddiqui et al., 2007). Addition of an artificially truncated
synaptotagmin or removal of phosphatidylserine from synapto-
brevin liposomes was necessary to stimulate calcium-depen-
dent SNARE-mediated liposomal fusion (Stein et al., 2007;
Tucker et al., 2004). We now show that a naturally-occurring
signaling molecule, sphingosine, can both accelerate synaptic
exocytosis and enhance SNARE assembly.
Preparation of vesicles for fusion with the plasma membrane
requires a series of steps: tethering, docking and priming. It is
well established that phospholipase C-mediated diacylglycerol
production plays an important role in priming of syntaxin for
SNARE-mediated vesicle fusion (Wierda et al., 2007). Our data
suggest that sphingosine can act as a priming factor for vesicular
synaptobrevin at the stage of SNARE complex assembly
preceding the calcium-triggered steps. This conclusion is sup-
ported by our biochemical data and by the ability of sphingosine
to increase the frequency of MEPPs in neuromuscular junctions
and sucrose-mediated neuronal exocytosis (Figures 3 and 4B).
Our results do not rule out additional effects of sphingosine in
synaptic vesicle exocytosis, for example, a change in biophys-
ical properties of the vesicular and plasma membranes. It is
well established that sphingosine concentrations are tightly
regulated inside the cell (Hannun and Obeid, 2008; Lahiri and
Futerman, 2007). Bulk concentration of free sphingosine in
mouse brain was estimated to be 0.5 mM (Dasgupta et al.,
2007) whereas estimates in rat pituitary cells gave a value of
5 mM (Blom et al., 2006). A recent study demonstrated the pres-
ence of sphingosine kinase in synapses arguing that production
of sphingosine and its further phosphorylation must take place in
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Figure 7. Sphingosine Inhibits Interaction of
the Cytoplasmic Part of Synaptobrevin with
Vesicular Membranes
(A) Protein profiles of purified synaptic vesicles (SV;
30 mg protein) and synaptobrevin liposomes (2 mg
protein) visualized in a Coomassie-stained SDS-
PAGE gel. Synaptotagmin, synaptophysin and
synaptobrevin are prominent synaptic vesicle
markers.
(B) Liposomes containing synaptobrevin (0.1 mg)
were incubated in the presence of soluble syn-
taxin/SNAP-25 heterodimer (0.3 mg) and increasing
concentrations of sphingosine. Immunoblot shows
the transition of monomeric synaptobrevin into the
SNARE complex. Note that a proportion of recon-
stituted synaptobrevin resides in the liposomal
interior (not shown) and therefore is not available
for syntaxin/SNAP-25 binding.
(C) The cytoplasmic domain of synaptobrevin (aa
1–96), immobilized on glutathione beads via a
GST tag, exhibits robust binding of phosphatidyl-
choline/phosphatidylserine liposomes labeled by
the fluorescent dye DiO. Sphingosine reduces the
ability of the cytoplasmic part of synaptobrevin to
bind the phospholipid membrane with an EC50 of
6 mM. Error bars represent SEM, n = 5.
(D) Graph showing increase in absorbance of lipo-
somal solution at 350 nm upon addition of 2.5 mM
GST-synaptobrevin (GST-Syb). This increase is
immediately reversed upon addition of sphingo-
sine (Sph, 50 mM, red curve).
(E) 2.5 mM GST-C2A domain of synaptotagmin-1
induces an increase in absorbance of liposome
solution in the presence of 1 mM free calcium.
This effect is insensitive to the addition of 50 mM
sphingosine (Sph). Vertical drops in absorbance
in (D) and (E) are due to dilution of reactions.
(F) Limited proteolysis of synaptic vesicles by V8
protease uncovers sensitivity of synaptobrevin, but not of synaptophysin, to sphingosine, as assessed by immunoblotting. Sphingosine-1-phosphate, ceramide,
or sphingomyelin (all 50 mM) did not significantly affect proteolysis of the synaptic vesicle proteins.
(G) Schematic showing sphingosine-mediated relief of the cytoplasmic part of synaptobrevin from inhibition by the vesicular membrane, a step necessary for
further interaction with the syntaxin/SNAP-25 heterodimer. Ternary SNARE complex formation leads to vesicle fusion with the plasma membrane.these secretory compartments (Kajimoto et al., 2007). Since the
Michaelis constant for sphingosine kinase was estimated to be
15 mM (Pitson et al., 2000), it is likely that such sphingosine
concentration can be achieved even if in a local setting. Both
synaptic vesicles and the plasma membrane carry sphingomye-
lin and ceramide (Lahiri and Futerman, 2007; Takamori et al.,
2006), and it has been estimated that a single vesicle contains
approx. 500 sphingomyelin molecules (Takamori et al., 2006).
Pertinently, experiments with sphingomyelinase demonstrated
that sufficient amounts of sphingosine can be released from
neuronal membranes for activation of both SNARE assembly
and exocytosis (Figure 5B and S2).
In summary, our study defines a new mechanism for synaptic
regulation: increased sphingosine production results in activa-
tion of synaptobrevin for SNARE complex assembly thereby
facilitating synaptic transmission. We demonstrated that the
unique properties of sphingosine are required for relieving the
amphipathic cytoplasmic part of synaptobrevin from its associ-
ation with the phospholipid membrane. This step is followed by
synaptobrevin engagement of syntaxin/SNAP-25 resulting inSNARE assembly and an augmented pool of readily-releasable
vesicles. Such a mechanism could explain, for example, stimula-
tion of neurotransmitter release by growth factors that activate
sphingomyelin hydrolysis (Blochl and Sirrenberg, 1996; Numa-
kawa et al., 2003). Importantly, it was recently shown that the
levels of sphingomyelin and its metabolites are altered in the
brain of patients with Alzheimer’s disease, Nieman-Pick’s
disease, and other neurological conditions (Dasgupta et al.,
2007; He et al., 2008; Matsuda et al., 2007; Rodriguez-Lafrasse
and Vanier, 1999) raising the possibility that deregulation of syn-
aptobrevin function takes place in these disorders. The identifi-
cation of synaptobrevin as a molecular target of sphingosine
may also have implications for current development of drugs
which act as sphingosine mimetics, for example, for the treat-
ment of multiple sclerosis (Kappos et al., 2006).
To gain a better understanding of sphingosine signaling in
subcellular settings, it will be useful to develop fluorescent
reporters that can sense local release of this lipid metabolite simi-
larly to a recent utilization of a protein domain in defining sites of
diacylglycerol production (Oancea et al., 1998). Further studiesNeuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc. 691
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sphingolipid metabolism in neurons allowing a better under-
standing of synaptobrevin regulation. The discovery of synapto-
brevin as a molecular target for sphingosine does not rule out
further targets in the complex array of molecules involved in
vesicle exocytosis but rather provides a new argument for explo-
ration of the role of lipids in vesicle fusion.
EXPERIMENTAL PROCEDURES
Purification of SNARE Proteins
Plasmids encoding glutathione S-transferase (GST) fusion proteins of rat syn-
taxin 1A (aa 1–261), synaptobrevin-2 (aa 1–96 and full-length), wild-type
SNAP-25B and SNAP-25B devoid of cysteines were described (Connell
et al., 2007; Kweon et al., 2003). Recombinant proteins were released from
GST by incubating beads with thrombin, and further purified on a Superdex
200 column equilibrated in 100 mM NaCl, 20 mM HEPES, pH 7.3 (buffer A).
The full-length synaptobrevin was purified in buffer A containing 0.8% n-octyl-
glucoside (Sigma). Brain syntaxin and SNAP-25 were purified as described (Hu
et al., 2002). Protein concentrations were estimated using Coomassie Plus
reagent (Pierce).
Lipid Screening
Recombinant syntaxin was mixed with an equimolar ratio of SNAP-25 over-
night at 4C to allow formation of syntaxin/SNAP-25 heterodimers. Synaptic
vesicles (1 mg of protein) were incubated with syntaxin1/SNAP-25 (2 mg) in
the presence of 50 mM lipids (Biomol) for 30 min at 22C. Reactions were
analyzed by SDS-PAGE followed by immunoblotting using a synaptobrevin
antibody (clone 69.1, Synaptic Systems).
Preparation of Liposomes and Liposome Binding Assays
Liposomes were prepared as described (Connell et al., 2008). The bead
binding assay was performed with fluorescent liposomes containing 1% DiO
essentially as described (Davletov and Sudhof, 1993). Bound lipid was quan-
tified using a fluorescence plate reader (Safire 2, Tecan). Real-time liposome
binding assay was performed as described (Connell et al., 2008). SNARE pro-
teoliposomes with lipid–protein ratio of 200:1 mol:mol were prepared as
described (Hu et al., 2002).
Isolation of Synaptic Fractions and Proteolysis of Synaptic Vesicles
Synaptosomes were prepared from rat brains using Ficoll (Sigma-Aldrich)
gradient as described (Davletov et al., 1998). To probe diffusion of sphingosine
across membranes, 3 ml of synaptosomes (1 mg protein/ml) were incubated
with 3H-labeled sphingosine (Perkin-Elmer) for 10 min at 37C and purified
again on the Ficoll gradient. Synaptosomes were disrupted by the hypo-
osmotic shock (10 mM HEPES; pH 7.3). Synaptic membranes were isolated
by centrifugation (20 min; 34,000 3 g; 4C). Synaptic vesicles were purified
as described (Hu et al., 2002). Radioactive sphingosine was quantified by
liquid scintillation. Electron microscopy was performed as described (Hu
et al., 2002). For limited proteolysis, synaptic vesicles (4 mg of protein) were
incubated in the presence of V8 protease (0.1 mM, Sigma) and lipids (50 mM)
for 20 min at 37C. Proteolysis was assessed by immunoblotting using synap-
tobrevin and synaptophysin antibodies (clones 69.1 and 7.2, Synaptic
Systems).
Release of Glutamate from Rat Brain Synaptosomes
Freshly-isolated synaptosomes were resuspended in synaptosomal buffer B
containing (in mM) 132 NaCl, 5 KCl, 20 HEPES, 1.2 NaH2PO4, 1.3 MgCl2,
0.15 Na2EGTA, 1 MgSO4, 5 NaHCO3, 10 D-glucose. Synaptosomes (1 mg
protein/ml) were incubated for 10 min at 37C with an equal volume of synap-
tosomal buffer B containing glutamate dehydrogenase (15 units/ml, Sigma)
and 3 mM NADP (Sigma) in the presence of either sphingosine solution or
vehicle, DMSO. Glutamate release was induced by addition of KCl (35 mM)
in the presence of 2 mM CaCl2 and monitored by following fluorescence
(McMahon et al., 1992). S. aureus sphingomyelinase (1 unit/ml, Sigma) was692 Neuron 62, 683–694, June 11, 2009 ª2009 Elsevier Inc.added to synaptosomes 15 min before addition of Ca2+/KCl. N-oleoylethanol-
amine (150 mM, Sigma) was added to synaptosomes 15 min prior to addition of
sphingomyelinase. Six nanomolar botulinum neurotoxin D was added to
synaptosomes 30 min prior to further additions.
Patch-Clamp Experiments in Rat Melanotrophs and Bovine
Chromaffin Cells
Animals were sacrificed in accordance with the European Communities
Council Directive (86/609/EEC). Melanotroph cell cultures were prepared
from rats as described (Rupnik and Zorec, 1992). Cells were patch-clamped
and their membrane capacitance (Cm) was measured at 22
C using the
uncompensated whole-cell technique with a dual-phase lock-in patch-clamp
amplifier (SWAM IIC, Celica, Slovenia). Melanotrophs were voltage clamped at
70 mV. Whole cell currents were stimulated with lock-in frequency of 1591 Hz
and were collected by Cell software (Celica). The recording bath solution
consisted of (mM) 130 NaCl, 10 HEPES/NaOH (pH 7.2), 10 glucose, 8 CaCl2,
1 MgCl2, and 5 KCl. Patch-clamp pipettes had a resistance of 1.5–4 MU and
were filled with a solution containing (mM): 150 KCl, 2 MgCl2, 10 HEPES/
KOH (pH 7.2), 2 Na2ATP, 2 EGTA, 1.74 CaCl2, yielding free [Ca
2+] of 1 mM.
Secretory responses were measured as a change in Cm (%) relative to the
resting Cm determined immediately after the establishment of the whole-cell
recording. The average steady-state currents were 12 ± 8 pA (control),
6 ± 16 pA (10 mM sphingosine), and 25 ± 16 pA (50 mM sphingosine); these
values were not statistically different (p = 0.7, Student’s t test).
In bovine chomaffin cell experiments, Ca2+ current peak (ICa) was recorded
in voltage-clamped cells under whole cell configuration at 25C. Cells were
dialyzed with a solution containing (mM): 10 NaCl, 100 CsCl, 20 TEA-Cl, 0.1
EGTA, 20 HEPES, 5 MgATP, 0.3 NaGTP (pH 7.2). During recordings, cells
were perfused with the Tyrode solution containing (mM) 137 NaCl, 1 MgCl2,
10 CaCl2, 10 glucose, 10 HEPES (pH 7.4). For patching the cells, pipettes of
3–5 MU resistance were used. Electrophysiological data were acquired with
an EPC-9 amplifier using the Pulse software (HEKA Elektronik). Cm changes
were estimated by the Lindau-Neher technique. A 400 ms sinusoidal wave
(1 kHz, 60 mV peak-to-peak amplitude) was given before the depolarizing
protocol followed by a 2 s sinusoidal wave of the same characteristics, allow-
ing calculations of Cm changes. Membrane current was sampled at 20 kHz.
Cells were held at 80 mV and depolarizing pulses at +10 mV were applied
at 1 min intervals. ICa was analyzed after the initial 5 ms of each depolarizing
pulse. To eliminate interference from Na+ channel gating (Horrigan and
Bookman, 1994), exocytic peak (DCm) was calculated by subtracting the basal
mean Cm obtained 400 ms prior to depolarization from that obtained 50 ms
after the end of the depolarizing pulse. Initial leak currents were not signifi-
cantly different: 11 ± 5 pA (control), 10 ± 8 pA (10 mM sphingosine), and
9 ± 4 pA (50 mM sphingosine).
Electrophysiology of Mouse Hippocampal Neurons
and Neuromuscular Junctions
Control and synaptobrevin-2-deficient dissociated cultures (courtesy of
Dr. Thomas C. Su¨dhof) were prepared as described (Schoch et al., 2001).
The hippocampus was dissected and dissociated from day 18 embryos, and
dissociated cells were plated on zero-thickness 12 mm glass coverslips and
stored at 37C with 5% CO2 in a humidified incubator. We used a modified Ty-
rode’s solution that contained (mM): 145 NaCl, 4 KCl, 2 MgCl2, 10 glucose, 10
HEPES, 2 CaCl2 (pH 7.4). Pyramidal neurons were whole-cell voltage clamped
at 70 mV with borosilicate glass electrodes (3–5 MU). Electrode solutions
contained (in mM) 105 Cs-methanesulphonate, 10 CsCl, 5 NaCl, 10 HEPES,
20 TEA-Cl, 4 Mg-ATP, 0.3 GTP, 0.6 EGTA, 10 QX-314 (pH 7.3, osmolarity
290 mOsM). Hippocampal cultures (10–21 days in vitro) were treated with
lipids (50 mM) for 10 min at 22C, washed thoroughly and then recordings
were performed. Field stimulation was achieved by applying 20 mA pulses
with a 1 ms duration using a bipolar platinum electrode; excitatory postsyn-
aptic currents (EPSCs) were measured in the presence of 50 mM picrotoxin.
Hypertonic sucrose responses were recorded by infusing modified Tyrode’s
solution containing 500 mM sucrose, 1 mM tetrodotoxin, 50 mM picrotoxin
for 30 s. For enzymatic experiments, rat hippocampal cultured neurons were
pretreated for 15 min with NOE (150 mM) followed by 10 min with sphingomye-
linase (1 unit/ml) before the application of hypertonic sucrose.
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mouse diaphragm at 22C. Muscles were continuously perfused with a solution
containing (mM): 130 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 11 glucose, 12 NaHPO4,
2.4 NaHCO3 (pH 7.3; gassed with 95% O2 and 5% CO2). Recordings of spon-
taneous miniature end-plate potentials (MEPPs) were performed using glass
microelectrodes as described (Giniatullin et al., 2006). The recorded MEPPs
were digitized at 50 kHz and analyzed off-line to calculate mean values of
signal frequency and amplitudes. Sphingosine was dissolved in DMSO and
then applied to the muscle via the superfusion system (2 ml/min) while sucrose
was applied by local fast microperfusion system using a glass pipette.
Estimation of Intraneuronal SNARE Assembly Using
Botulinum Neurotoxins
Following 30 min incubation with botulinum neurotoxins neurons were washed
with PBS, and lysed in SDS-containing sample buffer supplemented with
10 mM MgCl2 and 100 units/ml benzonase (Novagen). Proteins were assessed
by SDS-PAGE of boiled protein samples (10 mg protein) followed by immuno-
blotting using indicated antibodies.
SUPPLEMENTAL DATA
Supplemental Data include five figures and can be found with this article online
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